PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures acts as transaction advisor to Lausanne University Hospital (CHUV) and EPFL.

London, UK, 24 March, 2022

PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2 monoclonal antibodies to the newly founded biopharmaceutical company Aerium Therapeutics, based in Boston, MA, USA and Lausanne, Switzerland.

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to have advised CHUV and EPFL on their commercial terms for this break-through research that has significant potential to protect those who are left as most vulnerable to COVID-19.”

Dr. Giuseppe Pantaleo, Professor of Medicine at the CHUV, Head of Immunology and Allergy Division said “Our collaboration with Aerium Therapeutics will be key in delivering these antibodies to the clinical stage, where they have the potential to play an important role in the control and the prevention of COVID-19, particularly in all those who are not protected by vaccination.”

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

Oxford, UK, 15 October 2021

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.

Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with forming another research and development collaboration, and we look forward to seeing the results of combining IntoCell’s OHPAS linker and PMT payload technologies with Ab Studio’s innovative approach to antibody discovery.”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported IntoCell through the course of their discussion with Ab Studio for the research collaboration agreement. PharmaVentures hopes to continue the strong relationship with IntoCell in advising on their business development and licensing activities with our special insight accumulated over many years of supporting Korean biotech companies.”

 

For press enquiries, please contact:

Stephen Waterman

Managing Director

PharmaVentures Ltd

stephen@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures acts as advisor to IntoCell on their ongoing collaboration agreement with Cellectar

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

Oxford, UK, 15 July 2021

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

This follows the announcement that Cellectar and Intocell have expanded their collaboration using Intocell’s proprietary OHPAS linker and payload technologies to develop novel phospholipid ether drug conjugates (PDCs).

Steve Waterman, Managing Director at PharmaVentures, said “The collaboration with Cellectar has produced exciting preclinical results with multiple payloads, and the decision to advance these programmes into Investigational New Drug (IND) enabling studies is very encouraging.

We are looking forward to continuing to support Intocell with partnering of its Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker and its novel payloads that promise a wider therapeutic index over existing technology. Equally exciting is the progress with its pipeline of proprietary antibody drug conjugates (ADCs), the most advanced of which is its B7-H3 ADC. ”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures is pleased to have advised Intocell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar. PharmaVentures has a long and strong history in supporting our clients in their deal making activities due to our considerable transactional insight of the healthcare sector.  Furthermore, our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms.”

 

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

PharmaVentures acts as independent commercial expert

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM

Oxford, UK, 29 June 2021

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd.

Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our expert knowledge across the medical device sector, and in particular the wound care market, we were pleased to be able to provide an independent expert assessment of Spectral’s DeepView® Wound Imaging System with respect to their Initial Public Offering (IPO) on AIM.”

Fintan Walton, Chief Executive of PharmaVentures, said: “Providing independent expert commercial and technical insight in healthcare is a key component in contributing to understanding investment opportunities including IPOs and other transactions. PharmaVentures has a long and strong history in providing valuable commercial insight to our clients because of our deep commercial knowledge of the healthcare sector.”

Marc Dudek, Director of Business and Corporate Development at Spectral MD, said: “Spectral MD is delighted to IPO on the AIM market. This funding will be used to support further development of our diabetic foot ulcer application and to initiate our expansion into the UK and EU markets. We believe our differentiated technology has the potential to improve the standard of care for victims suffering from burn wounds and diabetic foot ulcers.”

PharmaVentures has a strong track record for writing Independent Expert Reports for companies listing on public markets such as AIM. These reports assist both the lay person and those with industry experience to understand how the company’s particular technology is positioned against competitors, where it brings technical or clinical benefits and how that relates to commercialisation.

 

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Oxford, UK, 3rd March 2021

PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.

 

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

enquiries@pharmaventures.com

+44 (0) 1865 332700